FDA-Approved Indication · ICD-10 G47.33

Getting Zepbound covered when your plan excludes weight loss

Zepbound is the only GLP-1 approved for moderate-to-severe Obstructive Sleep Apnea (OSA) in adults with obesity. When an employer excludes weight-loss drugs, coverage through an OSA diagnosis code runs through a completely different door.

The Strategy in One Minute

Many employer health plans have a strict exclusion that blocks coverage for weight loss. But insurance exclusions apply to the medical condition being treated, not the drug itself. If your doctor prescribes Zepbound to treat your sleep apnea, the plan's weight-loss exclusion rule does not apply.

Indication: Weight Management (Excluded / Denied)
Billed under an obesity diagnosis (ICD-10 E66.x). Standard employer plan riders explicitly exclude weight loss as a non-covered lifestyle benefit.

Indication: Obstructive Sleep Apnea (Covered Route)
Billed under moderate-to-severe OSA (ICD-10 G47.33). Approved by the FDA on December 20, 2024. Runs past the weight-loss exclusion because it treats a distinct medical disorder.

Clinical Criteria Checklist

To qualify for prior authorization or a formulary exception under the sleep apnea indication, chart notes and diagnostic reports must document:

Sleep Study (PSG / HSAT): Documented Apnea-Hypopnea Index (AHI) ≥ 15 events/hour. The FDA label covers moderate-to-severe OSA, which is AHI 15 and above; mild OSA (AHI 5–14) falls outside the labeled indication, and a request built on it should expect a denial regardless of symptoms.
Baseline BMI: BMI ≥ 30 kg/m² — the OSA indication is labeled for adults with obesity. The lower ≥ 27 with-comorbidity threshold belongs to the weight-management indication, which is the one the exclusion blocks, so it does not help here.
Diagnosis Coding: Primary ICD-10 code: G47.33 (Obstructive Sleep Apnea). Secondary: the obesity code the chart actually supports — E66.811–E66.813 by class, or E66.01 only where morbid (severe) obesity is documented. A code the chart does not back is itself a denial reason.
Therapeutic Equivalence: No therapeutic alternative exists on formulary: Zepbound (tirzepatide) is the only FDA-approved medication indicated for OSA.

Step-by-Step Appeal Roadmap

Step 1: Obtain your full diagnostic sleep study report
Request the complete polysomnography (PSG) or Home Sleep Apnea Test (HSAT) showing your numerical AHI score, oxygen desaturation nadir, and physician interpretation.
Step 2: Have your prescriber file the PA with primary code G47.33
Ensure the clinic submits the claim specifically for OSA (G47.33), citing the FDA December 2024 approval label, not under generalized weight reduction.
Step 3: If denied as "plan exclusion", file a Medical Necessity Appeal
Cite that the drug is prescribed to treat Obstructive Sleep Apnea — a recognized medical condition with cardiovascular and mortality risks — for which the plan covers treatment (such as CPAP and surgery).
Step 4: Request an External Independent Review (IRO)
If the internal appeal is upheld, escalate to external review. Independent physician reviewers must evaluate clinical evidence rather than plan cost-containment rules.

Sample Letter of Medical Necessity Wording

Your prescriber can incorporate this clinical justification into their prior-authorization packet or letter of medical necessity:

Physician Letter Template

Re: Prior Authorization / Medical Exception Request for Zepbound (tirzepatide) Patient: [Patient Name] | DOB: [DOB] | Member ID: [Member ID] Primary Diagnosis: Obstructive Sleep Apnea (ICD-10 G47.33) Secondary Diagnosis: Obesity (ICD-10: [code as documented, e.g. E66.811-E66.813 by class, or E66.01 if morbid obesity is charted]) Dear Medical Director, I am writing to request prior authorization and a formulary exception for Zepbound (tirzepatide) for my patient, [Patient Name], for the treatment of moderate-to-severe Obstructive Sleep Apnea (OSA) with obesity. On [Date], the patient underwent a diagnostic sleep study confirming moderate-to-severe OSA with an Apnea-Hypopnea Index (AHI) of [X] events/hour. Zepbound received FDA approval on December 20, 2024 as the first and only pharmaceutical agent indicated to treat moderate-to-severe OSA in adults with obesity. This prescription is not submitted for general cosmetic weight management, but for the direct treatment of documented obstructive sleep apnea, a recognized medical disorder with established cardiovascular and metabolic consequences. As there is currently no FDA-approved therapeutic equivalent on the formulary for this indication, denial of coverage prevents standard-of-care medical therapy. Sincerely, [Prescriber Name, MD/DO] [NPI Number]

Explore Your Coverage & Cost Options

While preparing your appeal, check your verified out-of-pocket costs and review PBM formulary policies:

Price Calculator

Price Zepbound Without Insurance

Compare verified manufacturer direct pricing and retail alternatives, dose by dose, with sources and dates on every figure.

Formulary Policies

View PBM Coverage Policies

Inspect prior authorization criteria and step-therapy rules for CVS Caremark, Express Scripts, and Optum Rx.